The 2021 WHO Classification of Tumors of the Pleura: Advances Since the 2015 Classification

Substantial changes in the 2021 WHO Classification of Tumors of the Pleura and Pericardium since the 2015 WHO Classification include the following: (1) pleural and pericardial tumors have been combined in one chapter whereas in the 2015 WHO, pericardial tumors were classified with cardiac tumors; (2...

Full description

Saved in:
Bibliographic Details
Published inJournal of thoracic oncology Vol. 17; no. 5; pp. 608 - 622
Main Authors Sauter, Jennifer L., Dacic, Sanja, Galateau-Salle, Francoise, Attanoos, Richard L., Butnor, Kelly J., Churg, Andrew, Husain, Aliya N., Kadota, Kyuichi, Khoor, Andras, Nicholson, Andrew G., Roggli, Victor, Schmitt, Fernando, Tsao, Ming-Sound, Travis, William D.
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.05.2022
Subjects
Biomarkers, Tumor - genetics
Histopathology
Homozygote
Humans
In Situ Hybridization, Fluorescence
Lung Neoplasms - pathology
Mesothelioma
Mesothelioma - pathology
Mesothelioma, Malignant
Pleura
Pleura - pathology
Pleural Neoplasms - pathology
Sequence Deletion
Tumor Suppressor Proteins - genetics
Ubiquitin Thiolesterase - genetics
World Health Organization
World Health Organization classification
World Health Organization classification
Mesothelioma
Histopathology
Pleura
Online AccessGet full text

Cover

Abstract Substantial changes in the 2021 WHO Classification of Tumors of the Pleura and Pericardium since the 2015 WHO Classification include the following: (1) pleural and pericardial tumors have been combined in one chapter whereas in the 2015 WHO, pericardial tumors were classified with cardiac tumors; (2) well-differentiated papillary mesothelioma has been renamed well-differentiated papillary mesothelial tumor given growing evidence that these tumors exhibit relatively indolent behavior; (3) localized and diffuse mesothelioma no longer include the term “malignant” as a prefix; (4) mesothelioma in situ has been added to the 2021 classification because these lesions can now be recognized by loss of BAP1 and/or MTAP by immunohistochemistry and/or CDKN2A homozygous deletion by fluorescence in situ hybridization; (5) the three main histologic subtypes (i.e., epithelioid, biphasic, and sarcomatoid) remain the same but architectural patterns and cytologic and stromal features are more formally incorporated into the 2021 classification on the basis of their prognostic significance; (6) nuclear grading for epithelioid diffuse mesothelioma is introduced, and it is recommended to record this and other histologically prognostic features in pathology reports; (7) BAP1, EZH2, and MTAP immunohistochemistry have been found to be useful in separating benign mesothelial proliferations from mesothelioma; (8) biphasic mesothelioma can be diagnosed in small biopsies having both epithelioid and sarcomatoid components even if the amount of one component is less than 10%; and (9) the most frequently altered genes in diffuse pleural mesothelioma include BAP1, CDKN2A, NF2, TP53, SETD2, and SETDB1.
AbstractList Substantial changes in the 2021 WHO Classification of Tumors of the Pleura and Pericardium since the 2015 WHO Classification include the following: (1) pleural and pericardial tumors have been combined in one chapter whereas in the 2015 WHO, pericardial tumors were classified with cardiac tumors; (2) well-differentiated papillary mesothelioma has been renamed well-differentiated papillary mesothelial tumor given growing evidence that these tumors exhibit relatively indolent behavior; (3) localized and diffuse mesothelioma no longer include the term “malignant” as a prefix; (4) mesothelioma in situ has been added to the 2021 classification because these lesions can now be recognized by loss of BAP1 and/or MTAP by immunohistochemistry and/or CDKN2A homozygous deletion by fluorescence in situ hybridization; (5) the three main histologic subtypes (i.e., epithelioid, biphasic, and sarcomatoid) remain the same but architectural patterns and cytologic and stromal features are more formally incorporated into the 2021 classification on the basis of their prognostic significance; (6) nuclear grading for epithelioid diffuse mesothelioma is introduced, and it is recommended to record this and other histologically prognostic features in pathology reports; (7) BAP1, EZH2, and MTAP immunohistochemistry have been found to be useful in separating benign mesothelial proliferations from mesothelioma; (8) biphasic mesothelioma can be diagnosed in small biopsies having both epithelioid and sarcomatoid components even if the amount of one component is less than 10%; and (9) the most frequently altered genes in diffuse pleural mesothelioma include BAP1, CDKN2A, NF2, TP53, SETD2, and SETDB1.
Substantial changes in the 2021 WHO Classification of Tumors of the Pleura and Pericardium since the 2015 WHO Classification include the following: (1) pleural and pericardial tumors have been combined in one chapter whereas in the 2015 WHO, pericardial tumors were classified with cardiac tumors; (2) well-differentiated papillary mesothelioma has been renamed well-differentiated papillary mesothelial tumor given growing evidence that these tumors exhibit relatively indolent behavior; (3) localized and diffuse mesothelioma no longer include the term "malignant" as a prefix; (4) mesothelioma in situ has been added to the 2021 classification because these lesions can now be recognized by loss of BAP1 and/or MTAP by immunohistochemistry and/or CDKN2A homozygous deletion by fluorescence in situ hybridization; (5) the three main histologic subtypes (i.e., epithelioid, biphasic, and sarcomatoid) remain the same but architectural patterns and cytologic and stromal features are more formally incorporated into the 2021 classification on the basis of their prognostic significance; (6) nuclear grading for epithelioid diffuse mesothelioma is introduced, and it is recommended to record this and other histologically prognostic features in pathology reports; (7) BAP1, EZH2, and MTAP immunohistochemistry have been found to be useful in separating benign mesothelial proliferations from mesothelioma; (8) biphasic mesothelioma can be diagnosed in small biopsies having both epithelioid and sarcomatoid components even if the amount of one component is less than 10%; and (9) the most frequently altered genes in diffuse pleural mesothelioma include BAP1, CDKN2A, NF2, TP53, SETD2, and SETDB1.Substantial changes in the 2021 WHO Classification of Tumors of the Pleura and Pericardium since the 2015 WHO Classification include the following: (1) pleural and pericardial tumors have been combined in one chapter whereas in the 2015 WHO, pericardial tumors were classified with cardiac tumors; (2) well-differentiated papillary mesothelioma has been renamed well-differentiated papillary mesothelial tumor given growing evidence that these tumors exhibit relatively indolent behavior; (3) localized and diffuse mesothelioma no longer include the term "malignant" as a prefix; (4) mesothelioma in situ has been added to the 2021 classification because these lesions can now be recognized by loss of BAP1 and/or MTAP by immunohistochemistry and/or CDKN2A homozygous deletion by fluorescence in situ hybridization; (5) the three main histologic subtypes (i.e., epithelioid, biphasic, and sarcomatoid) remain the same but architectural patterns and cytologic and stromal features are more formally incorporated into the 2021 classification on the basis of their prognostic significance; (6) nuclear grading for epithelioid diffuse mesothelioma is introduced, and it is recommended to record this and other histologically prognostic features in pathology reports; (7) BAP1, EZH2, and MTAP immunohistochemistry have been found to be useful in separating benign mesothelial proliferations from mesothelioma; (8) biphasic mesothelioma can be diagnosed in small biopsies having both epithelioid and sarcomatoid components even if the amount of one component is less than 10%; and (9) the most frequently altered genes in diffuse pleural mesothelioma include BAP1, CDKN2A, NF2, TP53, SETD2, and SETDB1.
Author Nicholson, Andrew G.
Roggli, Victor
Travis, William D.
Sauter, Jennifer L.
Attanoos, Richard L.
Galateau-Salle, Francoise
Dacic, Sanja
Kadota, Kyuichi
Butnor, Kelly J.
Tsao, Ming-Sound
Churg, Andrew
Khoor, Andras
Husain, Aliya N.
Schmitt, Fernando
Author_xml – sequence: 1
  givenname: Jennifer L.
  surname: Sauter
  fullname: Sauter, Jennifer L.
  email: sauterj@mskcc.org
  organization: Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York
– sequence: 2
  givenname: Sanja
  surname: Dacic
  fullname: Dacic, Sanja
  organization: Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
– sequence: 3
  givenname: Francoise
  surname: Galateau-Salle
  fullname: Galateau-Salle, Francoise
  organization: MESOPATH Centre Leon Berard, Lyon, France
– sequence: 4
  givenname: Richard L.
  surname: Attanoos
  fullname: Attanoos, Richard L.
  organization: Department of Cellular Pathology, University Hospital of Wales and School of Medicine, Cardiff University, Cardiff, Wales, United Kingdom
– sequence: 5
  givenname: Kelly J.
  surname: Butnor
  fullname: Butnor, Kelly J.
  organization: Department of Pathology & Laboratory Medicine, The University of Vermont Medical Center, Burlington, Vermont
– sequence: 6
  givenname: Andrew
  surname: Churg
  fullname: Churg, Andrew
  organization: Department of Pathology and Laboratory Medicine, Vancouver General Hospital and The University of British Columbia, Vancouver, British Columbia, Canada
– sequence: 7
  givenname: Aliya N.
  surname: Husain
  fullname: Husain, Aliya N.
  organization: Department of Pathology, The University of Chicago, Chicago, Illinois
– sequence: 8
  givenname: Kyuichi
  surname: Kadota
  fullname: Kadota, Kyuichi
  organization: Department of Pathology, Faculty of Medicine, Shimane University, Izumo, Japan
– sequence: 9
  givenname: Andras
  surname: Khoor
  fullname: Khoor, Andras
  organization: Department of Laboratory Medicine and Pathology, Mayo Clinic, Jacksonville, Florida
– sequence: 10
  givenname: Andrew G.
  surname: Nicholson
  fullname: Nicholson, Andrew G.
  organization: Royal Brompton and Harefield Hospitals, and National Heart and Lung Institute, Imperial College, London, United Kingdom
– sequence: 11
  givenname: Victor
  surname: Roggli
  fullname: Roggli, Victor
  organization: Department of Pathology, Duke University Medical Center, Durham, North Carolina
– sequence: 12
  givenname: Fernando
  surname: Schmitt
  fullname: Schmitt, Fernando
  organization: RISE@CINTESIS, Medical Faculty of Porto University, Porto, Portugal
– sequence: 13
  givenname: Ming-Sound
  surname: Tsao
  fullname: Tsao, Ming-Sound
  organization: Department of Pathology, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
– sequence: 14
  givenname: William D.
  surname: Travis
  fullname: Travis, William D.
  organization: Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35026477$$D View this record in MEDLINE/PubMed
BookMark eNp9kE1L5EAQhhtx8WPWP7CHJUcvE6s6_RXxIsPqCIILjuzBQ9PpdLCHTFq7kwH__SbOePHgqQrqfV6o55QcdqFzhPxCyBFQXKzzdf8ScgoUc6Q5IDsgJ8i5mGOh4HC_gxLsmJymtAZgHJg6IscFByqYlCfkefXisqkh-7d8yBatSck33prehy4LTbYaNiGmaevH4N_WDdFcZtf11nTWpezRj-PjRAH5F_4n-dGYNrmz_ZyRp5s_q8Vyfv9we7e4vp9bJkQ_r5mqrarKUhSyorwCJgxvwCowpVUUgQuppKwrtAyYKTgtJZbYNLQqjaqgmJHzXe9rDG-DS73e-GRd25rOhSFpKiiAlIhT9Pc-OlQbV-vX6DcmvutPIWNA7QI2hpSia7T1_cc3fTS-1Qh6cq_XenKvJ3MaqR7djyj9gn62fwtd7SA3Ctp6F3Wy3o1Sax-d7XUd_Hf4fxPtmbM
CitedBy_id crossref_primary_10_3892_ol_2022_13560
crossref_primary_10_1016_j_jtho_2022_08_017
crossref_primary_10_1007_s12262_022_03555_5
crossref_primary_10_1177_10732748231220805
crossref_primary_10_1016_j_ejrad_2025_111994
crossref_primary_10_1016_S1877_1203_22_00008_8
crossref_primary_10_3389_fonc_2025_1480197
crossref_primary_10_1016_j_jasc_2024_02_006
crossref_primary_10_1111_his_15007
crossref_primary_10_1007_s00330_024_10963_6
crossref_primary_10_1016_j_ejca_2023_113457
crossref_primary_10_12729_jbtr_2024_25_4_221
crossref_primary_10_3389_fpubh_2023_1156427
crossref_primary_10_3390_cancers15072072
crossref_primary_10_3390_cancers17020252
crossref_primary_10_1186_s13046_023_02889_6
crossref_primary_10_1016_j_biopha_2023_114651
crossref_primary_10_1136_jcp_2024_209592
crossref_primary_10_3390_jmp3040024
crossref_primary_10_1136_thorax_2023_220828
crossref_primary_10_1093_ehjcr_ytaf009
crossref_primary_10_1007_s12020_023_03328_4
crossref_primary_10_1111_his_15092
crossref_primary_10_1183_16000617_0174_2022
crossref_primary_10_1186_s13256_022_03420_9
crossref_primary_10_1111_resp_14648
crossref_primary_10_7759_cureus_52859
crossref_primary_10_1002_1878_0261_13351
crossref_primary_10_3390_diagnostics14202339
crossref_primary_10_1111_jmp_70001
crossref_primary_10_3389_fonc_2024_1359985
crossref_primary_10_1016_j_jtho_2024_04_019
crossref_primary_10_3390_jcm12227006
crossref_primary_10_1002_cncy_22705
crossref_primary_10_1148_rg_230079
crossref_primary_10_3390_ijms23105786
crossref_primary_10_1016_j_jtho_2024_03_007
crossref_primary_10_5493_wjem_v14_i3_91739
crossref_primary_10_1038_s41746_024_01003_0
crossref_primary_10_1007_s11684_024_1118_y
crossref_primary_10_1097_CEJ_0000000000000883
crossref_primary_10_1146_annurev_pathol_042420_092719
crossref_primary_10_1007_s00432_022_04295_5
crossref_primary_10_1016_j_jtho_2024_06_016
crossref_primary_10_3390_cancers15235534
crossref_primary_10_3390_jcm11154537
crossref_primary_10_3389_ftox_2024_1536344
crossref_primary_10_3892_ol_2024_14288
crossref_primary_10_1053_j_semnuclmed_2025_01_003
crossref_primary_10_3390_jcm13237322
crossref_primary_10_1097_RLU_0000000000004714
crossref_primary_10_1016_S1636_5410_24_49682_7
crossref_primary_10_3389_fonc_2022_1027149
crossref_primary_10_1007_s11604_023_01480_5
crossref_primary_10_1038_s41416_024_02830_4
crossref_primary_10_3390_life14101291
crossref_primary_10_3390_cancers16081587
crossref_primary_10_1016_j_modpat_2025_100706
crossref_primary_10_7759_cureus_70241
crossref_primary_10_1186_s10020_024_00835_6
crossref_primary_10_1007_s13665_024_00357_w
crossref_primary_10_3390_ijms241512426
crossref_primary_10_1111_apm_70006
crossref_primary_10_7759_cureus_67118
crossref_primary_10_3390_jcm13092600
crossref_primary_10_1111_1759_7714_14789
crossref_primary_10_3390_cancers16091719
crossref_primary_10_1097_LBR_0000000000000999
crossref_primary_10_1016_j_jtho_2022_07_006
crossref_primary_10_3390_jpm14040394
crossref_primary_10_3390_ijms24032874
crossref_primary_10_3390_ijms24043496
crossref_primary_10_1016_j_jtocrr_2022_100430
crossref_primary_10_1097_PAP_0000000000000387
crossref_primary_10_1183_23120541_00599_2022
crossref_primary_10_4081_cdr_12_12786
crossref_primary_10_1016_j_currproblcancer_2023_101017
crossref_primary_10_1038_s41598_024_84108_6
crossref_primary_10_7759_cureus_62212
crossref_primary_10_3390_curroncol30110687
crossref_primary_10_3390_cancers17030469
crossref_primary_10_1002_jso_27152
crossref_primary_10_3390_cancers16101817
crossref_primary_10_1016_j_lungcan_2024_108024
crossref_primary_10_1038_s44276_023_00004_y
crossref_primary_10_1038_s41698_024_00531_y
crossref_primary_10_1183_23120541_00860_2023
crossref_primary_10_1097_RTI_0000000000000809
crossref_primary_10_1111_his_15065
crossref_primary_10_3389_fimmu_2023_1333661
crossref_primary_10_1148_rg_220128
crossref_primary_10_5858_arpa_2023_0304_RA
crossref_primary_10_3390_cancers15204978
crossref_primary_10_1016_j_lungcan_2023_03_005
crossref_primary_10_1097_MNM_0000000000001702
crossref_primary_10_1186_s12995_024_00434_5
crossref_primary_10_3390_ijms231911248
crossref_primary_10_1002_cam4_6056
crossref_primary_10_1097_PAP_0000000000000403
crossref_primary_10_21518_ms2024_228
crossref_primary_10_3389_fcvm_2023_1182334
crossref_primary_10_3390_cancers15123261
crossref_primary_10_1186_s12885_023_11180_y
crossref_primary_10_12677_ACM_2024_142645
Cites_doi 10.5858/arpa.2018-0273-OA
10.1038/ng.3399
10.1016/j.lungcan.2018.07.041
10.1002/1878-0261.12651
10.1038/s41379-019-0364-z
10.1038/s41591-019-0583-3
10.1016/j.cllc.2019.04.010
10.1038/s41379-019-0330-9
10.1097/PAS.0000000000001416
10.1016/j.jss.2015.01.043
10.1038/s41379-019-0347-0
10.1097/00000478-200404000-00013
10.1016/j.lungcan.2020.09.026
10.1097/PAS.0000000000001188
10.1016/j.jtcvs.2008.02.069
10.1200/JCO.20005.14.589
10.3109/01913128809064207
10.1111/his.13123
10.1309/AJCPP5R2ZJZKCLWN
10.21037/tlcr-20-673
10.1002/cncy.22170
10.1038/ng.3520
10.1016/S0003-4975(99)01038-3
10.1002/cncy.21392
10.1158/2159-8290.CD-18-0804
10.1007/s00428-005-0035-y
10.1016/j.jtho.2019.08.2506
10.3389/fonc.2019.01519
10.1038/modpathol.2017.11
10.1200/JCO.2017.76.6394
10.1159/000501406
10.1111/j.1365-2559.1992.tb00915.x
10.1136/jcp.2005.028589
10.1016/j.lungcan.2019.02.004
10.1097/JTO.0b013e318211127a
10.1016/j.jasc.2019.12.003
10.5858/arpa.2013-0610-CP
10.1016/j.humpath.2016.01.010
10.1097/JTO.0b013e31826915f1
10.1016/j.jtho.2020.01.025
10.3389/fonc.2021.684025
10.1038/s41467-019-09307-6
10.1097/PAS.0b013e31802baad7
10.1016/j.humpath.2018.05.001
10.1038/s41379-021-00900-z
10.1111/his.13468
10.1080/019131290505176
10.1007/s11033-019-04715-9
10.1016/j.jtho.2019.10.023
10.1016/j.ebiom.2019.09.003
10.1016/0140-6736(91)90399-A
10.1097/JTO.0000000000000663
10.1016/j.lungcan.2018.03.009
10.1007/s00428-019-02674-x
10.1097/JTO.0000000000000436
10.5858/arpa.2013-0953-SA
10.5858/arpa.2012-0112-RA
10.1186/s13073-021-00931-w
10.1002/cncy.21660
10.1097/PAS.0000000000000864
10.1038/modpathol.2011.146
10.1200/JCO.1998.16.1.145
10.1002/cncr.10923
10.1038/modpathol.2017.61
10.1038/modpathol.2012.39
10.1038/s41379-019-0352-3
10.1097/PAS.0000000000000616
10.1038/modpathol.2011.202
10.1038/modpathol.2008.45
10.1136/jclinpath-2016-203993
10.1111/j.1440-1827.2009.02407.x
10.1038/modpathol.2017.153
10.1038/ng.912
10.21037/tlcr-20-1114
10.1038/s41379-019-0320-y
10.1002/cncy.22137
10.1038/modpathol.2017.170
10.1038/ng.855
10.1016/S2213-2600(18)30420-X
10.1097/JTO.0000000000000122
10.3390/cancers13112564
10.1038/modpathol.3880368
10.1038/modpathol.3800543
10.1111/j.1440-1827.2010.02560.x
10.1016/j.jtho.2015.11.005
10.1097/00000478-200110000-00012
10.1097/00000478-199610000-00007
ContentType Journal Article
Copyright 2022 International Association for the Study of Lung Cancer
Copyright © 2022 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.
Copyright_xml – notice: 2022 International Association for the Study of Lung Cancer
– notice: Copyright © 2022 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1016/j.jtho.2021.12.014
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList
MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1556-1380
EndPage 622
ExternalDocumentID 35026477
10_1016_j_jtho_2021_12_014
S1556086422000260
Genre Journal Article
Review
GrantInformation_xml – fundername: Bristol-Myers Squibb
  funderid: https://doi.org/10.13039/100002491
– fundername: Novartis
  funderid: https://doi.org/10.13039/100004336
– fundername: AstraZeneca
  funderid: https://doi.org/10.13039/100004325
GroupedDBID ---
.55
.XZ
.Z2
0R~
457
53G
5GY
5VS
6I.
9UZ
AACTN
AAEDW
AAFTH
AAIAV
AAKAS
AALRI
AAWTL
AAXUO
ABBUW
ABJNI
ABMAC
ABPMR
ABVKL
ACDDN
ACGFS
ACWDW
ACWRI
ADBBV
ADBIZ
ADEZE
ADZCM
AE3
AENEX
AEXQZ
AFTJW
AFTRI
AGHFR
AHPSJ
AITUG
AIZYK
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
AWKKM
BOYCO
C45
CS3
DU5
E.X
EBS
EJD
EX3
F5P
FDB
FL-
HZ~
IN~
KD2
NCXOZ
NTWIH
O9-
OFXIZ
OGEVE
OK1
OVD
P2P
ROL
S4S
SSZ
TEORI
V2I
W3M
WOQ
WOW
X7M
AAYWO
AAYXX
ACVFH
ADCNI
ADVLN
AEUPX
AFETI
AFJKZ
AFPUW
AGCQF
AIGII
AKBMS
AKRWK
AKYEP
APXCP
CITATION
0SF
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-c466t-d48dc8b99637b25b046a5f0c80a9c8210567877db1c404a35297191ff2b9a8b03
ISSN 1556-0864
1556-1380
IngestDate Fri Jul 11 04:58:57 EDT 2025
Thu Jan 02 22:53:56 EST 2025
Thu Apr 24 22:59:49 EDT 2025
Tue Jul 01 03:56:48 EDT 2025
Fri Feb 23 02:41:01 EST 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 5
Keywords World Health Organization classification
Mesothelioma
Histopathology
Pleura
Language English
License Copyright © 2022 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c466t-d48dc8b99637b25b046a5f0c80a9c8210567877db1c404a35297191ff2b9a8b03
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
OpenAccessLink http://www.jto.org/article/S1556086422000260/pdf
PMID 35026477
PQID 2620077110
PQPubID 23479
PageCount 15
ParticipantIDs proquest_miscellaneous_2620077110
pubmed_primary_35026477
crossref_citationtrail_10_1016_j_jtho_2021_12_014
crossref_primary_10_1016_j_jtho_2021_12_014
elsevier_sciencedirect_doi_10_1016_j_jtho_2021_12_014
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate May 2022
2022-05-00
20220501
PublicationDateYYYYMMDD 2022-05-01
PublicationDate_xml – month: 05
  year: 2022
  text: May 2022
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Journal of thoracic oncology
PublicationTitleAlternate J Thorac Oncol
PublicationYear 2022
Publisher Elsevier Inc
Publisher_xml – name: Elsevier Inc
References Wolff, Hammond, Hicks (bib56) 2014; 138
Menis, Pasello, Remon (bib76) 2021; 10
Meyerhoff, Yang, Speicher (bib13) 2015; 196
Marchevsky, Khoor, Walts (bib5) 2020; 33
Churg, Galateau-Salle, Roden (bib8) 2020; 33
Rusch, Rimner, Krug (bib17) 2014; 9
Nicholson, Sauter, Nowak (bib20) 2020; 15
Ordóñez (bib28) 2006; 19
Curran, Sahmoud, Therasse, van Meerbeeck, Postmus, Giaccone (bib11) 1998; 16
Bueno, Stawiski, Goldstein (bib63) 2016; 48
Minami, Jimbo, Tanaka (bib10) 2020; 476
Shia, Qin, Erlandson (bib26) 2005; 447
Soini, Kinnula, Kahlos, Pääkkö (bib41) 2006; 59
Lee, Molina, Sukov, Roden, Yi (bib7) 2018; 79
Mayall, Gibbs (bib23) 1992; 20
Sauter, Graham, Larsen (bib62) 2017; 30
Galateau Salle, Le Stang, Tirode (bib37) 2020; 15
Monaco, Shuai, Bansal, Krasinskas, Dacic (bib46) 2011; 135
Desmeules, Joubert, Zhang (bib75) 2017; 41
Henderson, Attwood, Constance, Shilkin, Steele (bib31) 1988; 12
Minato, Nojima, Kurose, Kinoshita (bib90) 2009; 59
Buonocore, Konno, Jungbluth (bib54) 2019; 127
Quetel, Meiller, Assié (bib67) 2020; 14
Rusch (bib14) 2012; 1
Perret, Chalabreysse, Watson (bib59) 2019; 43
Butnor, Sporn, Hammar, Roggli (bib3) 2001; 25
Wadowski, Bueno, De Rienzo (bib78) 2021; 11
Jo, Cibas, Pinkus (bib39) 2014; 122
Yao, Shia, Erlandson, Klimstra (bib33) 2004; 28
Zhang, Brambilla, Molyneaux (bib38) 2020; 44
Rekhtman, Montecalvo, Chang (bib60) 2020; 15
Hung, Dong, Dubuc, Dal Cin, Bueno, Chirieac (bib86) 2020; 33
Ordóñez (bib29) 2012; 25
Chiosea, Krasinskas, Cagle, Mitchell, Zander, Dacic (bib74) 2008; 21
Lo Iacono, Monica, Righi (bib71) 2015; 10
Shinozaki-Ushiku, Ushiku, Morita, Anraku, Nakajima, Fukayama (bib47) 2017; 70
Hasegawa, Matsuno, Shimoda, Umeda, Yokoyama, Hirohashi (bib57) 2001; 14
Combaz-Lair, Galateau-Sallé, McLeer-Florin (bib84) 2016; 52
Meiller, Montagne, Hirsch (bib68) 2021; 13
Brosseau, Danel, Scherpereel (bib82) 2019; 20
Kadota, Suzuki, Colovos (bib21) 2012; 25
Brcic, Klikovits, Megyesfalvi (bib80) 2021; 10
Flores, Routledge, Seshan (bib12) 2008; 136
Kawai, Hiroi, Nakanishi (bib32) 2010; 60
Disselhorst, Quispel-Janssen, Lalezari (bib77) 2019; 7
Churg, Hwang, Tan (bib9) 2018; 72
Galateau-Sallé, Attanoos, Gibbs (bib30) 2007; 31
Illei, Ladanyi, Rusch, Zakowski (bib50) 2003; 99
Fusco, Vaira, Righi (bib81) 2020; 150
Rusch, Venkatraman (bib18) 1999; 68
Testa, Cheung, Pei (bib48) 2011; 43
Dacic, Le Stang, Husain (bib36) 2020; 33
Kadota, Suzuki, Sima, Rusch, Adusumilli, Travis (bib27) 2011; 6
Churg, Nabeshima, Ali, Bruno, Fernandez-Cuesta, Galateau-Salle (bib34) 2018; 124
Sobhani, Roviello, Pivetta (bib83) 2019; 46
Muller, Victoria Lai, Adusumilli (bib85) 2020; 33
Ordóñez (bib24) 2012; 25
Blum, Meiller, Quetel (bib65) 2019; 10
Nicolini, Bocchini, Bronte (bib73) 2020; 9
Kelly (bib89) 1991; 338
(bib1) 2021
Le Loarer, Watson, Pierron (bib58) 2015; 47
Courtiol, Maussion, Moarii (bib35) 2019; 25
Patel, Borczuk, Siddiqui (bib40) 2020; 9
Alcala, Mangiante, Le-Stang (bib66) 2019; 48
Yoshida, Kobayashi, Kubo (bib61) 2017; 30
Galateau-Sallé, Vignaud, Burke (bib4) 2004; 28
Ang, Tan, Karim, Wong (bib42) 2020; 64
Yoshimura, Kinoshita, Hamasaki (bib49) 2019; 130
Travis, Brambilla, Burke, Marx, Nicholson (bib2) 2015; 10
Rusch, Giroux (bib15) 2012; 1
Jain, Nambirajan, Borczuk (bib55) 2019; 127
Churg, Galateau-Salle (bib44) 2012; 136
Kaplan, Tazelaar, Hayashi, Schroer, Travis (bib88) Oct 1996; 20
Bott, Brevet, Taylor (bib43) 2011; 43
Berg, Dacic, Miller, Cheung, Churg (bib51) 2018; 142
van Meerbeeck, Gaafar, Manegold (bib19) 2005; 23
Rosen, Karrison, Ananthanarayanan (bib22) 2018; 31
Rusch, Giroux, Kennedy (bib16) 2012; 7
Kindler, Ismaila, Armato (bib72) 2018; 36
Sneddon, Dick, Lee (bib70) 2018; 119
Hmeljak, Sanchez-Vega, Hoadley (bib64) 2018; 8
Galateau-Salle, Churg, Roggli, Travis (bib6) 2016; 11
Goode, Joseph, Stevers (bib87) 2018; 31
Hwang, Pyott, Rodriguez (bib45) 2016; 40
Alchami, Attanoos, Bamber (bib25) 2017; 70
Fitzgibbons, Bradley, Fatheree (bib52) 2014; 138
Sauter, Grogg, Vrana, Law, Halvorson, Henry (bib53) 2016; 124
Roy, Galateau-Sallé, Le Stang (bib69) 2022; 35
Napoli, Listì, Zambelli (bib79) 2021; 13
Roy (10.1016/j.jtho.2021.12.014_bib69) 2022; 35
Muller (10.1016/j.jtho.2021.12.014_bib85) 2020; 33
Nicolini (10.1016/j.jtho.2021.12.014_bib73) 2020; 9
Alcala (10.1016/j.jtho.2021.12.014_bib66) 2019; 48
Hwang (10.1016/j.jtho.2021.12.014_bib45) 2016; 40
Combaz-Lair (10.1016/j.jtho.2021.12.014_bib84) 2016; 52
Shia (10.1016/j.jtho.2021.12.014_bib26) 2005; 447
Shinozaki-Ushiku (10.1016/j.jtho.2021.12.014_bib47) 2017; 70
(10.1016/j.jtho.2021.12.014_bib1) 2021
Napoli (10.1016/j.jtho.2021.12.014_bib79) 2021; 13
Mayall (10.1016/j.jtho.2021.12.014_bib23) 1992; 20
Jain (10.1016/j.jtho.2021.12.014_bib55) 2019; 127
Perret (10.1016/j.jtho.2021.12.014_bib59) 2019; 43
Meiller (10.1016/j.jtho.2021.12.014_bib68) 2021; 13
Rosen (10.1016/j.jtho.2021.12.014_bib22) 2018; 31
Galateau-Sallé (10.1016/j.jtho.2021.12.014_bib4) 2004; 28
Ang (10.1016/j.jtho.2021.12.014_bib42) 2020; 64
Lo Iacono (10.1016/j.jtho.2021.12.014_bib71) 2015; 10
Blum (10.1016/j.jtho.2021.12.014_bib65) 2019; 10
Kadota (10.1016/j.jtho.2021.12.014_bib27) 2011; 6
Bott (10.1016/j.jtho.2021.12.014_bib43) 2011; 43
Sauter (10.1016/j.jtho.2021.12.014_bib62) 2017; 30
Ordóñez (10.1016/j.jtho.2021.12.014_bib28) 2006; 19
Marchevsky (10.1016/j.jtho.2021.12.014_bib5) 2020; 33
Rusch (10.1016/j.jtho.2021.12.014_bib17) 2014; 9
Desmeules (10.1016/j.jtho.2021.12.014_bib75) 2017; 41
Yoshimura (10.1016/j.jtho.2021.12.014_bib49) 2019; 130
Yoshida (10.1016/j.jtho.2021.12.014_bib61) 2017; 30
Rusch (10.1016/j.jtho.2021.12.014_bib14) 2012; 1
Berg (10.1016/j.jtho.2021.12.014_bib51) 2018; 142
Rusch (10.1016/j.jtho.2021.12.014_bib18) 1999; 68
Butnor (10.1016/j.jtho.2021.12.014_bib3) 2001; 25
Churg (10.1016/j.jtho.2021.12.014_bib8) 2020; 33
Henderson (10.1016/j.jtho.2021.12.014_bib31) 1988; 12
Ordóñez (10.1016/j.jtho.2021.12.014_bib24) 2012; 25
Menis (10.1016/j.jtho.2021.12.014_bib76) 2021; 10
Kelly (10.1016/j.jtho.2021.12.014_bib89) 1991; 338
van Meerbeeck (10.1016/j.jtho.2021.12.014_bib19) 2005; 23
Minami (10.1016/j.jtho.2021.12.014_bib10) 2020; 476
Sauter (10.1016/j.jtho.2021.12.014_bib53) 2016; 124
Minato (10.1016/j.jtho.2021.12.014_bib90) 2009; 59
Wolff (10.1016/j.jtho.2021.12.014_bib56) 2014; 138
Kawai (10.1016/j.jtho.2021.12.014_bib32) 2010; 60
Kadota (10.1016/j.jtho.2021.12.014_bib21) 2012; 25
Illei (10.1016/j.jtho.2021.12.014_bib50) 2003; 99
Soini (10.1016/j.jtho.2021.12.014_bib41) 2006; 59
Galateau Salle (10.1016/j.jtho.2021.12.014_bib37) 2020; 15
Brcic (10.1016/j.jtho.2021.12.014_bib80) 2021; 10
Courtiol (10.1016/j.jtho.2021.12.014_bib35) 2019; 25
Churg (10.1016/j.jtho.2021.12.014_bib34) 2018; 124
Curran (10.1016/j.jtho.2021.12.014_bib11) 1998; 16
Churg (10.1016/j.jtho.2021.12.014_bib44) 2012; 136
Le Loarer (10.1016/j.jtho.2021.12.014_bib58) 2015; 47
Bueno (10.1016/j.jtho.2021.12.014_bib63) 2016; 48
Meyerhoff (10.1016/j.jtho.2021.12.014_bib13) 2015; 196
Patel (10.1016/j.jtho.2021.12.014_bib40) 2020; 9
Goode (10.1016/j.jtho.2021.12.014_bib87) 2018; 31
Kindler (10.1016/j.jtho.2021.12.014_bib72) 2018; 36
Testa (10.1016/j.jtho.2021.12.014_bib48) 2011; 43
Fusco (10.1016/j.jtho.2021.12.014_bib81) 2020; 150
Galateau-Sallé (10.1016/j.jtho.2021.12.014_bib30) 2007; 31
Buonocore (10.1016/j.jtho.2021.12.014_bib54) 2019; 127
Hung (10.1016/j.jtho.2021.12.014_bib86) 2020; 33
Travis (10.1016/j.jtho.2021.12.014_bib2) 2015; 10
Galateau-Salle (10.1016/j.jtho.2021.12.014_bib6) 2016; 11
Churg (10.1016/j.jtho.2021.12.014_bib9) 2018; 72
Rusch (10.1016/j.jtho.2021.12.014_bib15) 2012; 1
Rekhtman (10.1016/j.jtho.2021.12.014_bib60) 2020; 15
Brosseau (10.1016/j.jtho.2021.12.014_bib82) 2019; 20
Alchami (10.1016/j.jtho.2021.12.014_bib25) 2017; 70
Hasegawa (10.1016/j.jtho.2021.12.014_bib57) 2001; 14
Quetel (10.1016/j.jtho.2021.12.014_bib67) 2020; 14
Sobhani (10.1016/j.jtho.2021.12.014_bib83) 2019; 46
Zhang (10.1016/j.jtho.2021.12.014_bib38) 2020; 44
Fitzgibbons (10.1016/j.jtho.2021.12.014_bib52) 2014; 138
Kaplan (10.1016/j.jtho.2021.12.014_bib88) 1996; 20
Flores (10.1016/j.jtho.2021.12.014_bib12) 2008; 136
Monaco (10.1016/j.jtho.2021.12.014_bib46) 2011; 135
Hmeljak (10.1016/j.jtho.2021.12.014_bib64) 2018; 8
Disselhorst (10.1016/j.jtho.2021.12.014_bib77) 2019; 7
Lee (10.1016/j.jtho.2021.12.014_bib7) 2018; 79
Nicholson (10.1016/j.jtho.2021.12.014_bib20) 2020; 15
Jo (10.1016/j.jtho.2021.12.014_bib39) 2014; 122
Ordóñez (10.1016/j.jtho.2021.12.014_bib29) 2012; 25
Dacic (10.1016/j.jtho.2021.12.014_bib36) 2020; 33
Yao (10.1016/j.jtho.2021.12.014_bib33) 2004; 28
Rusch (10.1016/j.jtho.2021.12.014_bib16) 2012; 7
Wadowski (10.1016/j.jtho.2021.12.014_bib78) 2021; 11
Sneddon (10.1016/j.jtho.2021.12.014_bib70) 2018; 119
Chiosea (10.1016/j.jtho.2021.12.014_bib74) 2008; 21
References_xml – volume: 14
  start-page: 655
  year: 2001
  end-page: 663
  ident: bib57
  article-title: Proximal-type epithelioid sarcoma: a clinicopathologic study of 20 cases
  publication-title: Mod Pathol
– volume: 124
  start-page: 89
  year: 2016
  end-page: 100
  ident: bib53
  article-title: Young investigator challenge: validation and optimization of immunohistochemistry protocols for use on cellient cell block specimens
  publication-title: Cancer Cytopathol
– volume: 25
  start-page: 260
  year: 2012
  end-page: 271
  ident: bib21
  article-title: A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma
  publication-title: Mod Pathol
– volume: 9
  start-page: 1519
  year: 2020
  ident: bib73
  article-title: Malignant pleural mesothelioma: state-of-the-art on current therapies and promises for the future
  publication-title: Front Oncol
– volume: 136
  start-page: 1217
  year: 2012
  end-page: 1226
  ident: bib44
  article-title: The separation of benign and malignant mesothelial proliferations
  publication-title: Arch Pathol Lab Med
– volume: 14
  start-page: 1207
  year: 2020
  end-page: 1223
  ident: bib67
  article-title: Genetic alterations of malignant pleural mesothelioma: association with tumor heterogeneity and overall survival
  publication-title: Mol Oncol
– volume: 10
  start-page: 2988
  year: 2021
  end-page: 3000
  ident: bib76
  article-title: Immunotherapy in malignant pleural mesothelioma: a review of literature data
  publication-title: Transl Lung Cancer Res
– volume: 1
  start-page: 523
  year: 2012
  end-page: 531
  ident: bib14
  article-title: Extrapleural pneumonectomy and extended pleurectomy/decortication for malignant pleural mesothelioma: the Memorial Sloan-Kettering Cancer Center approach
  publication-title: Ann Cardiothorac Surg
– volume: 70
  start-page: 179
  year: 2017
  end-page: 182
  ident: bib25
  article-title: Myxoid variant epithelioid pleural mesothelioma defines a favourable prognosis group: an analysis of 191 patients with pleural malignant mesothelioma
  publication-title: J Clin Pathol
– volume: 48
  start-page: 407
  year: 2016
  end-page: 416
  ident: bib63
  article-title: Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations
  publication-title: Nat Genet
– volume: 13
  start-page: 113
  year: 2021
  ident: bib68
  article-title: Multi-site tumor sampling highlights molecular intra-tumor heterogeneity in malignant pleural mesothelioma
  publication-title: Genome Med
– volume: 150
  start-page: 53
  year: 2020
  end-page: 61
  ident: bib81
  article-title: Characterization of the immune microenvironment in malignant pleural mesothelioma reveals prognostic subgroups of patients
  publication-title: Lung Cancer
– volume: 33
  start-page: 303
  year: 2020
  end-page: 311
  ident: bib85
  article-title: V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma
  publication-title: Mod Pathol
– volume: 59
  start-page: 250
  year: 2006
  end-page: 254
  ident: bib41
  article-title: Claudins in differential diagnosis between mesothelioma and metastatic adenocarcinoma of the pleura
  publication-title: J Clin Pathol
– volume: 21
  start-page: 742
  year: 2008
  end-page: 747
  ident: bib74
  article-title: Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas
  publication-title: Mod Pathol
– volume: 40
  start-page: 714
  year: 2016
  end-page: 718
  ident: bib45
  article-title: BAP1 Immunohistochemistry and p16 FISH in the diagnosis of sarcomatous and desmoplastic mesotheliomas
  publication-title: Am J Surg Pathol
– volume: 447
  start-page: 828
  year: 2005
  end-page: 834
  ident: bib26
  article-title: Malignant mesothelioma with a pronounced myxoid stroma: a clinical and pathological evaluation of 19 cases
  publication-title: Virchows Arch
– volume: 9
  start-page: 271
  year: 2014
  end-page: 272
  ident: bib17
  article-title: The challenge of malignant pleural mesothelioma: new directions
  publication-title: J Thorac Oncol
– volume: 60
  start-page: 566
  year: 2010
  end-page: 574
  ident: bib32
  article-title: Lymphohistiocytoid mesothelioma of the pleura
  publication-title: Pathol Int
– volume: 43
  start-page: 668
  year: 2011
  end-page: 672
  ident: bib43
  article-title: The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma
  publication-title: Nat Genet
– volume: 196
  start-page: 23
  year: 2015
  end-page: 32
  ident: bib13
  article-title: Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database
  publication-title: J Surg Res
– volume: 119
  start-page: 64
  year: 2018
  end-page: 70
  ident: bib70
  article-title: Malignant cells from pleural fluids in malignant mesothelioma patients reveal novel mutations
  publication-title: Lung Cancer
– volume: 6
  start-page: 896
  year: 2011
  end-page: 904
  ident: bib27
  article-title: Pleomorphic epithelioid diffuse malignant pleural mesothelioma: a clinicopathological review and conceptual proposal to reclassify as biphasic or sarcomatoid mesothelioma
  publication-title: J Thorac Oncol
– volume: 15
  start-page: 29
  year: 2020
  end-page: 49
  ident: bib20
  article-title: EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach
  publication-title: J Thorac Oncol
– volume: 15
  start-page: 1037
  year: 2020
  end-page: 1053
  ident: bib37
  article-title: Comprehensive molecular and pathologic evaluation of transitional mesothelioma assisted by deep learning approach: a multi-institutional study of the international mesothelioma panel from the MESOPATH Reference Center
  publication-title: J Thorac Oncol
– volume: 35
  start-page: 82
  year: 2022
  end-page: 86
  ident: bib69
  article-title: Molecular characterization of pleomorphic mesothelioma: a multi-institutional study
  publication-title: Mod Pathol
– volume: 20
  start-page: e564
  year: 2019
  end-page: e575
  ident: bib82
  article-title: Shorter survival in malignant pleural mesothelioma patients with high PD-L1 expression associated with sarcomatoid or biphasic histology subtype: a series of 214 cases from the Bio-MAPS cohort
  publication-title: Clin Lung Cancer
– volume: 52
  start-page: 9
  year: 2016
  end-page: 18
  ident: bib84
  article-title: Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas
  publication-title: Hum Pathol
– volume: 7
  start-page: 260
  year: 2019
  end-page: 270
  ident: bib77
  article-title: Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial
  publication-title: Lancet Respir Med
– year: 2021
  ident: bib1
  article-title: WHO Classification of Tumours: Thoracic Tumours
– volume: 43
  start-page: 1022
  year: 2011
  end-page: 1025
  ident: bib48
  article-title: Germline BAP1 mutations predispose to malignant mesothelioma
  publication-title: Nat Genet
– volume: 33
  start-page: 281
  year: 2020
  end-page: 296
  ident: bib5
  article-title: Localized malignant mesothelioma, an unusual and poorly characterized neoplasm of serosal origin: best current evidence from the literature and the International Mesothelioma Panel
  publication-title: Mod Pathol
– volume: 142
  start-page: 1549
  year: 2018
  end-page: 1553
  ident: bib51
  article-title: Utility of methylthioadenosine phosphorylase compared with BAP1 immunohistochemistry, and CDKN2A and NF2 fluorescence in situ hybridization in separating reactive mesothelial proliferations from epithelioid malignant mesotheliomas
  publication-title: Arch Pathol Lab Med
– volume: 47
  start-page: 1200
  year: 2015
  end-page: 1205
  ident: bib58
  article-title: SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas
  publication-title: Nat Genet
– volume: 15
  start-page: 231
  year: 2020
  end-page: 247
  ident: bib60
  article-title: SMARCA4-deficient thoracic sarcomatoid tumors represent primarily smoking-related undifferentiated carcinomas rather than primary thoracic sarcomas
  publication-title: J Thorac Oncol
– volume: 36
  start-page: 1343
  year: 2018
  end-page: 1373
  ident: bib72
  article-title: Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline
  publication-title: J Clin Oncol
– volume: 79
  start-page: 168
  year: 2018
  end-page: 176
  ident: bib7
  article-title: BAP1 loss is unusual in well-differentiated papillary mesothelioma and may predict development of malignant mesothelioma
  publication-title: Hum Pathol
– volume: 30
  start-page: 797
  year: 2017
  end-page: 809
  ident: bib61
  article-title: Clinicopathological and molecular characterization of SMARCA4-deficient thoracic sarcomas with comparison to potentially related entities
  publication-title: Mod Pathol
– volume: 338
  start-page: 257
  year: 1991
  ident: bib89
  article-title: European drug regulation
  publication-title: Lancet
– volume: 11
  start-page: 142
  year: 2016
  end-page: 154
  ident: bib6
  article-title: The 2015 World Health Organization classification of tumors of the pleura: advances since the 2004 classification
  publication-title: J Thorac Oncol
– volume: 136
  start-page: 605
  year: 2008
  end-page: 610
  ident: bib12
  article-title: The impact of lymph node station on survival in 348 patients with surgically resected malignant pleural mesothelioma: implications for revision of the American Joint Committee on Cancer staging system
  publication-title: J Thorac Cardiovasc Surg
– volume: 122
  start-page: 299
  year: 2014
  end-page: 306
  ident: bib39
  article-title: Claudin-4 immunohistochemistry is highly effective in distinguishing adenocarcinoma from malignant mesothelioma in effusion cytology
  publication-title: Cancer Cytopathol
– volume: 28
  start-page: 213
  year: 2004
  end-page: 228
  ident: bib33
  article-title: Lymphohistiocytoid mesothelioma: a clinical, immunohistochemical and ultrastructural study of four cases and literature review
  publication-title: Ultrastruct Pathol
– volume: 25
  start-page: 1304
  year: 2001
  end-page: 1309
  ident: bib3
  article-title: Well-differentiated papillary mesothelioma
  publication-title: Am J Surg Pathol
– volume: 33
  start-page: 255
  year: 2020
  end-page: 262
  ident: bib36
  article-title: Interobserver variation in the assessment of the sarcomatoid and transitional components in biphasic mesotheliomas
  publication-title: Mod Pathol
– volume: 41
  start-page: 980
  year: 2017
  end-page: 988
  ident: bib75
  article-title: A subset of malignant mesotheliomas in young adults are associated with recurrent EWSR1/FUS-ATF1 fusions
  publication-title: Am J Surg Pathol
– volume: 25
  start-page: 1011
  year: 2012
  end-page: 1022
  ident: bib29
  article-title: Pleomorphic mesothelioma: report of 10 cases
  publication-title: Mod Pathol
– volume: 135
  start-page: 619
  year: 2011
  end-page: 627
  ident: bib46
  article-title: The diagnostic utility of p16 FISH and GLUT-1 immunohistochemical analysis in mesothelial proliferations
  publication-title: Am J Clin Pathol
– volume: 70
  start-page: 722
  year: 2017
  end-page: 733
  ident: bib47
  article-title: Diagnostic utility of BAP1 and EZH2 expression in malignant mesothelioma
  publication-title: Histopathology
– volume: 10
  start-page: 492
  year: 2015
  end-page: 499
  ident: bib71
  article-title: Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study
  publication-title: J Thorac Oncol
– volume: 138
  start-page: 1432
  year: 2014
  end-page: 1443
  ident: bib52
  article-title: Principles of analytic validation of immunohistochemical assays: guideline from the College of American Pathologists Pathology and Laboratory Quality Center
  publication-title: Arch Pathol Lab Med
– volume: 31
  start-page: 711
  year: 2007
  end-page: 716
  ident: bib30
  article-title: Lymphohistiocytoid variant of malignant mesothelioma of the pleura: a series of 22 cases
  publication-title: Am J Surg Pathol
– volume: 9
  start-page: 146
  year: 2020
  end-page: 151
  ident: bib40
  article-title: Utility of Claudin-4 versus BerEP4 and B72.3 in pleural fluids with metastatic lung adenocarcinoma
  publication-title: J Am Soc Cytopathol
– volume: 10
  start-page: 1333
  year: 2019
  ident: bib65
  article-title: Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications
  publication-title: Nat Commun
– volume: 46
  start-page: 2713
  year: 2019
  end-page: 2720
  ident: bib83
  article-title: Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma
  publication-title: Mol Biol Rep
– volume: 16
  start-page: 145
  year: 1998
  end-page: 152
  ident: bib11
  article-title: Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience
  publication-title: J Clin Oncol
– volume: 33
  start-page: 297
  year: 2020
  end-page: 302
  ident: bib8
  article-title: Malignant mesothelioma in situ: morphologic features and clinical outcome
  publication-title: Mod Pathol
– volume: 127
  start-page: 643
  year: 2019
  end-page: 649
  ident: bib54
  article-title: CytoLyt fixation significantly inhibits MIB1 immunoreactivity whereas alternative Ki-67 clone 30-9 is not susceptible to the inhibition: critical diagnostic implications
  publication-title: Cancer Cytopathol
– volume: 30
  start-page: 1422
  year: 2017
  end-page: 1432
  ident: bib62
  article-title: SMARCA4-deficient thoracic sarcoma: a distinctive clinicopathological entity with undifferentiated rhabdoid mrophology and aggressive behaviro
  publication-title: Mod Pathol
– volume: 59
  start-page: 567
  year: 2009
  end-page: 571
  ident: bib90
  article-title: Adenomatoid tumor of the pleura
  publication-title: Pathol Int
– volume: 7
  start-page: 1631
  year: 2012
  end-page: 1639
  ident: bib16
  article-title: Initial analysis of the international association for the study of lung cancer mesothelioma database
  publication-title: J Thorac Oncol
– volume: 28
  start-page: 534
  year: 2004
  end-page: 540
  ident: bib4
  article-title: Well-differentiated papillary mesothelioma of the pleura: a series of 24 cases
  publication-title: Am J Surg Pathol
– volume: 13
  start-page: 2564
  year: 2021
  ident: bib79
  article-title: Pathological characterization of Tumor Immune Microenvironment (TIME) in malignant pleural mesothelioma
  publication-title: Cancers (Basel)
– volume: 33
  start-page: 271
  year: 2020
  end-page: 280
  ident: bib86
  article-title: Molecular characterization of localized pleural mesothelioma
  publication-title: Mod Pathol
– volume: 99
  start-page: 51
  year: 2003
  end-page: 56
  ident: bib50
  article-title: The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions
  publication-title: Cancer
– volume: 476
  start-page: 469
  year: 2020
  end-page: 473
  ident: bib10
  article-title: Malignant mesothelioma in situ diagnosed by methylthioadenosine phosphorylase loss and homozygous deletion of CDKN2A: a case report
  publication-title: Virchows Arch
– volume: 1
  start-page: 438
  year: 2012
  end-page: 448
  ident: bib15
  article-title: Do we need a revised staging system for malignant pleural mesothelioma? Analysis of the IASLC database
  publication-title: Ann Cardiothorac Surg
– volume: 25
  start-page: 689
  year: 2012
  end-page: 698
  ident: bib24
  article-title: Mesotheliomas with small cell features: report of eight cases
  publication-title: Mod Pathol
– volume: 124
  start-page: 95
  year: 2018
  end-page: 101
  ident: bib34
  article-title: Highlights of the 14th international mesothelioma interest group meeting: pathologic separation of benign from malignant mesothelial proliferations and histologic/molecular analysis of malignant mesothelioma subtypes
  publication-title: Lung Cancer
– volume: 8
  start-page: 1548
  year: 2018
  end-page: 1565
  ident: bib64
  article-title: integrative molecular characterization of malignant pleural mesothelioma
  publication-title: Cancer Discov
– volume: 20
  start-page: 47
  year: 1992
  end-page: 51
  ident: bib23
  article-title: The histology and immunohistochemistry of small cell mesothelioma
  publication-title: Histopathology
– volume: 130
  start-page: 187
  year: 2019
  end-page: 193
  ident: bib49
  article-title: Highly expressed EZH2 in combination with BAP1 and MTAP loss, as detected by immunohistochemistry, is useful for differentiating malignant pleural mesothelioma from reactive mesothelial hyperplasia
  publication-title: Lung Cancer
– volume: 10
  start-page: 1240
  year: 2015
  end-page: 1242
  ident: bib2
  article-title: Introduction to the 2015 World Health Organization classification of tumors of the lung, pleura, thymus, and heart
  publication-title: J Thorac Oncol
– volume: 44
  start-page: 347
  year: 2020
  end-page: 356
  ident: bib38
  article-title: Utility of nuclear grading system in epithelioid malignant pleural mesothelioma in biopsy-heavy setting: an external validation study of 563 cases
  publication-title: Am J Surg Pathol
– volume: 10
  start-page: 1594
  year: 2021
  end-page: 1607
  ident: bib80
  article-title: Prognostic impact of PD-1 and PD-L1 expression in malignant pleural mesothelioma: an international multicenter study
  publication-title: Transl Lung Cancer Res
– volume: 23
  start-page: 6881
  year: 2005
  end-page: 6889
  ident: bib19
  article-title: Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada
  publication-title: J Clin Oncol
– volume: 64
  start-page: 248
  year: 2020
  end-page: 255
  ident: bib42
  article-title: Diagnostic value of the EZH2 immunomarker in malignant effusion cytology
  publication-title: Acta Cytol
– volume: 31
  start-page: 660
  year: 2018
  end-page: 673
  ident: bib87
  article-title: Adenomatoid tumors of the male and female genital tract are defined by TRAF7 mutations that drive aberrant NF-kB pathway activation
  publication-title: Mod Pathol
– volume: 127
  start-page: 325
  year: 2019
  end-page: 339
  ident: bib55
  article-title: Immunocytochemistry for predictive biomarker testing in lung cancer cytology
  publication-title: Cancer Cytopathol
– volume: 25
  start-page: 1519
  year: 2019
  end-page: 1525
  ident: bib35
  article-title: Deep learning-based classification of mesothelioma improves prediction of patient outcome
  publication-title: Nat Med
– volume: 12
  start-page: 367
  year: 1988
  end-page: 384
  ident: bib31
  article-title: Lymphohistiocytoid mesothelioma: a rare lymphomatoid variant of predominantly sarcomatoid mesothelioma
  publication-title: Ultrastruct Pathol
– volume: 31
  start-page: 598
  year: 2018
  end-page: 606
  ident: bib22
  article-title: Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: a multi-institutional study
  publication-title: Mod Pathol
– volume: 11
  start-page: 684025
  year: 2021
  ident: bib78
  article-title: Immune microenvironment and genetics in malignant pleural mesothelioma
  publication-title: Front Oncol
– volume: 48
  start-page: 191
  year: 2019
  end-page: 202
  ident: bib66
  article-title: Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactions
  publication-title: EBioMedicine
– volume: 43
  start-page: 455
  year: 2019
  end-page: 465
  ident: bib59
  article-title: SMARCA4-deficient thoracic sarcomas: clinicopathologic study of 30 cases with an emphasis on their nosology and differential diagnoses
  publication-title: Am J Surg Pathol
– volume: 20
  start-page: 1219
  year: Oct 1996
  end-page: 1223
  ident: bib88
  article-title: Adenomatoid tumors of the pleura
  publication-title: Am J Surg Pathol
– volume: 68
  start-page: 1799
  year: 1999
  end-page: 1804
  ident: bib18
  article-title: Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically
  publication-title: Ann Thorac Surg
– volume: 19
  start-page: 373
  year: 2006
  end-page: 383
  ident: bib28
  article-title: Mesothelioma with rhabdoid features: an ultrastructural and immunohistochemical study of 10 cases
  publication-title: Mod Pathol
– volume: 138
  start-page: 241
  year: 2014
  end-page: 256
  ident: bib56
  article-title: Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update
  publication-title: Arch Pathol Lab Med
– volume: 72
  start-page: 1033
  year: 2018
  end-page: 1038
  ident: bib9
  article-title: Malignant mesothelioma in situ
  publication-title: Histopathology
– volume: 142
  start-page: 1549
  year: 2018
  ident: 10.1016/j.jtho.2021.12.014_bib51
  article-title: Utility of methylthioadenosine phosphorylase compared with BAP1 immunohistochemistry, and CDKN2A and NF2 fluorescence in situ hybridization in separating reactive mesothelial proliferations from epithelioid malignant mesotheliomas
  publication-title: Arch Pathol Lab Med
  doi: 10.5858/arpa.2018-0273-OA
– volume: 47
  start-page: 1200
  year: 2015
  ident: 10.1016/j.jtho.2021.12.014_bib58
  article-title: SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas
  publication-title: Nat Genet
  doi: 10.1038/ng.3399
– volume: 124
  start-page: 95
  year: 2018
  ident: 10.1016/j.jtho.2021.12.014_bib34
  article-title: Highlights of the 14th international mesothelioma interest group meeting: pathologic separation of benign from malignant mesothelial proliferations and histologic/molecular analysis of malignant mesothelioma subtypes
  publication-title: Lung Cancer
  doi: 10.1016/j.lungcan.2018.07.041
– volume: 14
  start-page: 1207
  year: 2020
  ident: 10.1016/j.jtho.2021.12.014_bib67
  article-title: Genetic alterations of malignant pleural mesothelioma: association with tumor heterogeneity and overall survival
  publication-title: Mol Oncol
  doi: 10.1002/1878-0261.12651
– volume: 33
  start-page: 303
  year: 2020
  ident: 10.1016/j.jtho.2021.12.014_bib85
  article-title: V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma
  publication-title: Mod Pathol
  doi: 10.1038/s41379-019-0364-z
– volume: 25
  start-page: 1519
  year: 2019
  ident: 10.1016/j.jtho.2021.12.014_bib35
  article-title: Deep learning-based classification of mesothelioma improves prediction of patient outcome
  publication-title: Nat Med
  doi: 10.1038/s41591-019-0583-3
– volume: 20
  start-page: e564
  year: 2019
  ident: 10.1016/j.jtho.2021.12.014_bib82
  article-title: Shorter survival in malignant pleural mesothelioma patients with high PD-L1 expression associated with sarcomatoid or biphasic histology subtype: a series of 214 cases from the Bio-MAPS cohort
  publication-title: Clin Lung Cancer
  doi: 10.1016/j.cllc.2019.04.010
– volume: 33
  start-page: 271
  year: 2020
  ident: 10.1016/j.jtho.2021.12.014_bib86
  article-title: Molecular characterization of localized pleural mesothelioma
  publication-title: Mod Pathol
  doi: 10.1038/s41379-019-0330-9
– volume: 44
  start-page: 347
  year: 2020
  ident: 10.1016/j.jtho.2021.12.014_bib38
  article-title: Utility of nuclear grading system in epithelioid malignant pleural mesothelioma in biopsy-heavy setting: an external validation study of 563 cases
  publication-title: Am J Surg Pathol
  doi: 10.1097/PAS.0000000000001416
– volume: 196
  start-page: 23
  year: 2015
  ident: 10.1016/j.jtho.2021.12.014_bib13
  article-title: Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database
  publication-title: J Surg Res
  doi: 10.1016/j.jss.2015.01.043
– volume: 33
  start-page: 297
  year: 2020
  ident: 10.1016/j.jtho.2021.12.014_bib8
  article-title: Malignant mesothelioma in situ: morphologic features and clinical outcome
  publication-title: Mod Pathol
  doi: 10.1038/s41379-019-0347-0
– volume: 28
  start-page: 534
  year: 2004
  ident: 10.1016/j.jtho.2021.12.014_bib4
  article-title: Well-differentiated papillary mesothelioma of the pleura: a series of 24 cases
  publication-title: Am J Surg Pathol
  doi: 10.1097/00000478-200404000-00013
– volume: 150
  start-page: 53
  year: 2020
  ident: 10.1016/j.jtho.2021.12.014_bib81
  article-title: Characterization of the immune microenvironment in malignant pleural mesothelioma reveals prognostic subgroups of patients
  publication-title: Lung Cancer
  doi: 10.1016/j.lungcan.2020.09.026
– volume: 43
  start-page: 455
  year: 2019
  ident: 10.1016/j.jtho.2021.12.014_bib59
  article-title: SMARCA4-deficient thoracic sarcomas: clinicopathologic study of 30 cases with an emphasis on their nosology and differential diagnoses
  publication-title: Am J Surg Pathol
  doi: 10.1097/PAS.0000000000001188
– volume: 136
  start-page: 605
  year: 2008
  ident: 10.1016/j.jtho.2021.12.014_bib12
  article-title: The impact of lymph node station on survival in 348 patients with surgically resected malignant pleural mesothelioma: implications for revision of the American Joint Committee on Cancer staging system
  publication-title: J Thorac Cardiovasc Surg
  doi: 10.1016/j.jtcvs.2008.02.069
– volume: 23
  start-page: 6881
  year: 2005
  ident: 10.1016/j.jtho.2021.12.014_bib19
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.20005.14.589
– volume: 12
  start-page: 367
  year: 1988
  ident: 10.1016/j.jtho.2021.12.014_bib31
  article-title: Lymphohistiocytoid mesothelioma: a rare lymphomatoid variant of predominantly sarcomatoid mesothelioma
  publication-title: Ultrastruct Pathol
  doi: 10.3109/01913128809064207
– volume: 70
  start-page: 722
  year: 2017
  ident: 10.1016/j.jtho.2021.12.014_bib47
  article-title: Diagnostic utility of BAP1 and EZH2 expression in malignant mesothelioma
  publication-title: Histopathology
  doi: 10.1111/his.13123
– volume: 135
  start-page: 619
  year: 2011
  ident: 10.1016/j.jtho.2021.12.014_bib46
  article-title: The diagnostic utility of p16 FISH and GLUT-1 immunohistochemical analysis in mesothelial proliferations
  publication-title: Am J Clin Pathol
  doi: 10.1309/AJCPP5R2ZJZKCLWN
– volume: 10
  start-page: 2988
  year: 2021
  ident: 10.1016/j.jtho.2021.12.014_bib76
  article-title: Immunotherapy in malignant pleural mesothelioma: a review of literature data
  publication-title: Transl Lung Cancer Res
  doi: 10.21037/tlcr-20-673
– volume: 127
  start-page: 643
  year: 2019
  ident: 10.1016/j.jtho.2021.12.014_bib54
  article-title: CytoLyt fixation significantly inhibits MIB1 immunoreactivity whereas alternative Ki-67 clone 30-9 is not susceptible to the inhibition: critical diagnostic implications
  publication-title: Cancer Cytopathol
  doi: 10.1002/cncy.22170
– volume: 48
  start-page: 407
  year: 2016
  ident: 10.1016/j.jtho.2021.12.014_bib63
  article-title: Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations
  publication-title: Nat Genet
  doi: 10.1038/ng.3520
– volume: 68
  start-page: 1799
  year: 1999
  ident: 10.1016/j.jtho.2021.12.014_bib18
  article-title: Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically
  publication-title: Ann Thorac Surg
  doi: 10.1016/S0003-4975(99)01038-3
– volume: 122
  start-page: 299
  year: 2014
  ident: 10.1016/j.jtho.2021.12.014_bib39
  article-title: Claudin-4 immunohistochemistry is highly effective in distinguishing adenocarcinoma from malignant mesothelioma in effusion cytology
  publication-title: Cancer Cytopathol
  doi: 10.1002/cncy.21392
– volume: 8
  start-page: 1548
  year: 2018
  ident: 10.1016/j.jtho.2021.12.014_bib64
  article-title: integrative molecular characterization of malignant pleural mesothelioma
  publication-title: Cancer Discov
  doi: 10.1158/2159-8290.CD-18-0804
– volume: 447
  start-page: 828
  year: 2005
  ident: 10.1016/j.jtho.2021.12.014_bib26
  article-title: Malignant mesothelioma with a pronounced myxoid stroma: a clinical and pathological evaluation of 19 cases
  publication-title: Virchows Arch
  doi: 10.1007/s00428-005-0035-y
– volume: 15
  start-page: 29
  year: 2020
  ident: 10.1016/j.jtho.2021.12.014_bib20
  article-title: EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach
  publication-title: J Thorac Oncol
  doi: 10.1016/j.jtho.2019.08.2506
– volume: 9
  start-page: 1519
  year: 2020
  ident: 10.1016/j.jtho.2021.12.014_bib73
  article-title: Malignant pleural mesothelioma: state-of-the-art on current therapies and promises for the future
  publication-title: Front Oncol
  doi: 10.3389/fonc.2019.01519
– volume: 30
  start-page: 797
  year: 2017
  ident: 10.1016/j.jtho.2021.12.014_bib61
  article-title: Clinicopathological and molecular characterization of SMARCA4-deficient thoracic sarcomas with comparison to potentially related entities
  publication-title: Mod Pathol
  doi: 10.1038/modpathol.2017.11
– volume: 36
  start-page: 1343
  year: 2018
  ident: 10.1016/j.jtho.2021.12.014_bib72
  article-title: Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2017.76.6394
– volume: 64
  start-page: 248
  year: 2020
  ident: 10.1016/j.jtho.2021.12.014_bib42
  article-title: Diagnostic value of the EZH2 immunomarker in malignant effusion cytology
  publication-title: Acta Cytol
  doi: 10.1159/000501406
– volume: 20
  start-page: 47
  year: 1992
  ident: 10.1016/j.jtho.2021.12.014_bib23
  article-title: The histology and immunohistochemistry of small cell mesothelioma
  publication-title: Histopathology
  doi: 10.1111/j.1365-2559.1992.tb00915.x
– volume: 59
  start-page: 250
  year: 2006
  ident: 10.1016/j.jtho.2021.12.014_bib41
  article-title: Claudins in differential diagnosis between mesothelioma and metastatic adenocarcinoma of the pleura
  publication-title: J Clin Pathol
  doi: 10.1136/jcp.2005.028589
– volume: 130
  start-page: 187
  year: 2019
  ident: 10.1016/j.jtho.2021.12.014_bib49
  article-title: Highly expressed EZH2 in combination with BAP1 and MTAP loss, as detected by immunohistochemistry, is useful for differentiating malignant pleural mesothelioma from reactive mesothelial hyperplasia
  publication-title: Lung Cancer
  doi: 10.1016/j.lungcan.2019.02.004
– volume: 6
  start-page: 896
  year: 2011
  ident: 10.1016/j.jtho.2021.12.014_bib27
  article-title: Pleomorphic epithelioid diffuse malignant pleural mesothelioma: a clinicopathological review and conceptual proposal to reclassify as biphasic or sarcomatoid mesothelioma
  publication-title: J Thorac Oncol
  doi: 10.1097/JTO.0b013e318211127a
– volume: 9
  start-page: 146
  year: 2020
  ident: 10.1016/j.jtho.2021.12.014_bib40
  article-title: Utility of Claudin-4 versus BerEP4 and B72.3 in pleural fluids with metastatic lung adenocarcinoma
  publication-title: J Am Soc Cytopathol
  doi: 10.1016/j.jasc.2019.12.003
– volume: 138
  start-page: 1432
  year: 2014
  ident: 10.1016/j.jtho.2021.12.014_bib52
  article-title: Principles of analytic validation of immunohistochemical assays: guideline from the College of American Pathologists Pathology and Laboratory Quality Center
  publication-title: Arch Pathol Lab Med
  doi: 10.5858/arpa.2013-0610-CP
– volume: 52
  start-page: 9
  year: 2016
  ident: 10.1016/j.jtho.2021.12.014_bib84
  article-title: Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas
  publication-title: Hum Pathol
  doi: 10.1016/j.humpath.2016.01.010
– volume: 7
  start-page: 1631
  year: 2012
  ident: 10.1016/j.jtho.2021.12.014_bib16
  article-title: Initial analysis of the international association for the study of lung cancer mesothelioma database
  publication-title: J Thorac Oncol
  doi: 10.1097/JTO.0b013e31826915f1
– volume: 15
  start-page: 1037
  year: 2020
  ident: 10.1016/j.jtho.2021.12.014_bib37
  article-title: Comprehensive molecular and pathologic evaluation of transitional mesothelioma assisted by deep learning approach: a multi-institutional study of the international mesothelioma panel from the MESOPATH Reference Center
  publication-title: J Thorac Oncol
  doi: 10.1016/j.jtho.2020.01.025
– volume: 11
  start-page: 684025
  year: 2021
  ident: 10.1016/j.jtho.2021.12.014_bib78
  article-title: Immune microenvironment and genetics in malignant pleural mesothelioma
  publication-title: Front Oncol
  doi: 10.3389/fonc.2021.684025
– year: 2021
  ident: 10.1016/j.jtho.2021.12.014_bib1
– volume: 1
  start-page: 523
  year: 2012
  ident: 10.1016/j.jtho.2021.12.014_bib14
  article-title: Extrapleural pneumonectomy and extended pleurectomy/decortication for malignant pleural mesothelioma: the Memorial Sloan-Kettering Cancer Center approach
  publication-title: Ann Cardiothorac Surg
– volume: 10
  start-page: 1333
  year: 2019
  ident: 10.1016/j.jtho.2021.12.014_bib65
  article-title: Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications
  publication-title: Nat Commun
  doi: 10.1038/s41467-019-09307-6
– volume: 31
  start-page: 711
  year: 2007
  ident: 10.1016/j.jtho.2021.12.014_bib30
  article-title: Lymphohistiocytoid variant of malignant mesothelioma of the pleura: a series of 22 cases
  publication-title: Am J Surg Pathol
  doi: 10.1097/PAS.0b013e31802baad7
– volume: 79
  start-page: 168
  year: 2018
  ident: 10.1016/j.jtho.2021.12.014_bib7
  article-title: BAP1 loss is unusual in well-differentiated papillary mesothelioma and may predict development of malignant mesothelioma
  publication-title: Hum Pathol
  doi: 10.1016/j.humpath.2018.05.001
– volume: 35
  start-page: 82
  year: 2022
  ident: 10.1016/j.jtho.2021.12.014_bib69
  article-title: Molecular characterization of pleomorphic mesothelioma: a multi-institutional study
  publication-title: Mod Pathol
  doi: 10.1038/s41379-021-00900-z
– volume: 72
  start-page: 1033
  year: 2018
  ident: 10.1016/j.jtho.2021.12.014_bib9
  article-title: Malignant mesothelioma in situ
  publication-title: Histopathology
  doi: 10.1111/his.13468
– volume: 28
  start-page: 213
  year: 2004
  ident: 10.1016/j.jtho.2021.12.014_bib33
  article-title: Lymphohistiocytoid mesothelioma: a clinical, immunohistochemical and ultrastructural study of four cases and literature review
  publication-title: Ultrastruct Pathol
  doi: 10.1080/019131290505176
– volume: 46
  start-page: 2713
  year: 2019
  ident: 10.1016/j.jtho.2021.12.014_bib83
  article-title: Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma
  publication-title: Mol Biol Rep
  doi: 10.1007/s11033-019-04715-9
– volume: 15
  start-page: 231
  year: 2020
  ident: 10.1016/j.jtho.2021.12.014_bib60
  article-title: SMARCA4-deficient thoracic sarcomatoid tumors represent primarily smoking-related undifferentiated carcinomas rather than primary thoracic sarcomas
  publication-title: J Thorac Oncol
  doi: 10.1016/j.jtho.2019.10.023
– volume: 48
  start-page: 191
  year: 2019
  ident: 10.1016/j.jtho.2021.12.014_bib66
  article-title: Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactions
  publication-title: EBioMedicine
  doi: 10.1016/j.ebiom.2019.09.003
– volume: 338
  start-page: 257
  year: 1991
  ident: 10.1016/j.jtho.2021.12.014_bib89
  article-title: European drug regulation
  publication-title: Lancet
  doi: 10.1016/0140-6736(91)90399-A
– volume: 10
  start-page: 1240
  year: 2015
  ident: 10.1016/j.jtho.2021.12.014_bib2
  article-title: Introduction to the 2015 World Health Organization classification of tumors of the lung, pleura, thymus, and heart
  publication-title: J Thorac Oncol
  doi: 10.1097/JTO.0000000000000663
– volume: 1
  start-page: 438
  year: 2012
  ident: 10.1016/j.jtho.2021.12.014_bib15
  article-title: Do we need a revised staging system for malignant pleural mesothelioma? Analysis of the IASLC database
  publication-title: Ann Cardiothorac Surg
– volume: 119
  start-page: 64
  year: 2018
  ident: 10.1016/j.jtho.2021.12.014_bib70
  article-title: Malignant cells from pleural fluids in malignant mesothelioma patients reveal novel mutations
  publication-title: Lung Cancer
  doi: 10.1016/j.lungcan.2018.03.009
– volume: 476
  start-page: 469
  year: 2020
  ident: 10.1016/j.jtho.2021.12.014_bib10
  article-title: Malignant mesothelioma in situ diagnosed by methylthioadenosine phosphorylase loss and homozygous deletion of CDKN2A: a case report
  publication-title: Virchows Arch
  doi: 10.1007/s00428-019-02674-x
– volume: 10
  start-page: 492
  year: 2015
  ident: 10.1016/j.jtho.2021.12.014_bib71
  article-title: Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study
  publication-title: J Thorac Oncol
  doi: 10.1097/JTO.0000000000000436
– volume: 138
  start-page: 241
  year: 2014
  ident: 10.1016/j.jtho.2021.12.014_bib56
  article-title: Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update
  publication-title: Arch Pathol Lab Med
  doi: 10.5858/arpa.2013-0953-SA
– volume: 136
  start-page: 1217
  year: 2012
  ident: 10.1016/j.jtho.2021.12.014_bib44
  article-title: The separation of benign and malignant mesothelial proliferations
  publication-title: Arch Pathol Lab Med
  doi: 10.5858/arpa.2012-0112-RA
– volume: 13
  start-page: 113
  year: 2021
  ident: 10.1016/j.jtho.2021.12.014_bib68
  article-title: Multi-site tumor sampling highlights molecular intra-tumor heterogeneity in malignant pleural mesothelioma
  publication-title: Genome Med
  doi: 10.1186/s13073-021-00931-w
– volume: 124
  start-page: 89
  year: 2016
  ident: 10.1016/j.jtho.2021.12.014_bib53
  article-title: Young investigator challenge: validation and optimization of immunohistochemistry protocols for use on cellient cell block specimens
  publication-title: Cancer Cytopathol
  doi: 10.1002/cncy.21660
– volume: 41
  start-page: 980
  year: 2017
  ident: 10.1016/j.jtho.2021.12.014_bib75
  article-title: A subset of malignant mesotheliomas in young adults are associated with recurrent EWSR1/FUS-ATF1 fusions
  publication-title: Am J Surg Pathol
  doi: 10.1097/PAS.0000000000000864
– volume: 25
  start-page: 260
  year: 2012
  ident: 10.1016/j.jtho.2021.12.014_bib21
  article-title: A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma
  publication-title: Mod Pathol
  doi: 10.1038/modpathol.2011.146
– volume: 16
  start-page: 145
  year: 1998
  ident: 10.1016/j.jtho.2021.12.014_bib11
  article-title: Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.1998.16.1.145
– volume: 99
  start-page: 51
  year: 2003
  ident: 10.1016/j.jtho.2021.12.014_bib50
  article-title: The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions
  publication-title: Cancer
  doi: 10.1002/cncr.10923
– volume: 30
  start-page: 1422
  year: 2017
  ident: 10.1016/j.jtho.2021.12.014_bib62
  article-title: SMARCA4-deficient thoracic sarcoma: a distinctive clinicopathological entity with undifferentiated rhabdoid mrophology and aggressive behaviro
  publication-title: Mod Pathol
  doi: 10.1038/modpathol.2017.61
– volume: 25
  start-page: 1011
  year: 2012
  ident: 10.1016/j.jtho.2021.12.014_bib29
  article-title: Pleomorphic mesothelioma: report of 10 cases
  publication-title: Mod Pathol
  doi: 10.1038/modpathol.2012.39
– volume: 33
  start-page: 281
  year: 2020
  ident: 10.1016/j.jtho.2021.12.014_bib5
  article-title: Localized malignant mesothelioma, an unusual and poorly characterized neoplasm of serosal origin: best current evidence from the literature and the International Mesothelioma Panel
  publication-title: Mod Pathol
  doi: 10.1038/s41379-019-0352-3
– volume: 40
  start-page: 714
  year: 2016
  ident: 10.1016/j.jtho.2021.12.014_bib45
  article-title: BAP1 Immunohistochemistry and p16 FISH in the diagnosis of sarcomatous and desmoplastic mesotheliomas
  publication-title: Am J Surg Pathol
  doi: 10.1097/PAS.0000000000000616
– volume: 25
  start-page: 689
  year: 2012
  ident: 10.1016/j.jtho.2021.12.014_bib24
  article-title: Mesotheliomas with small cell features: report of eight cases
  publication-title: Mod Pathol
  doi: 10.1038/modpathol.2011.202
– volume: 21
  start-page: 742
  year: 2008
  ident: 10.1016/j.jtho.2021.12.014_bib74
  article-title: Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas
  publication-title: Mod Pathol
  doi: 10.1038/modpathol.2008.45
– volume: 70
  start-page: 179
  year: 2017
  ident: 10.1016/j.jtho.2021.12.014_bib25
  article-title: Myxoid variant epithelioid pleural mesothelioma defines a favourable prognosis group: an analysis of 191 patients with pleural malignant mesothelioma
  publication-title: J Clin Pathol
  doi: 10.1136/jclinpath-2016-203993
– volume: 59
  start-page: 567
  year: 2009
  ident: 10.1016/j.jtho.2021.12.014_bib90
  article-title: Adenomatoid tumor of the pleura
  publication-title: Pathol Int
  doi: 10.1111/j.1440-1827.2009.02407.x
– volume: 31
  start-page: 660
  year: 2018
  ident: 10.1016/j.jtho.2021.12.014_bib87
  article-title: Adenomatoid tumors of the male and female genital tract are defined by TRAF7 mutations that drive aberrant NF-kB pathway activation
  publication-title: Mod Pathol
  doi: 10.1038/modpathol.2017.153
– volume: 43
  start-page: 1022
  year: 2011
  ident: 10.1016/j.jtho.2021.12.014_bib48
  article-title: Germline BAP1 mutations predispose to malignant mesothelioma
  publication-title: Nat Genet
  doi: 10.1038/ng.912
– volume: 10
  start-page: 1594
  year: 2021
  ident: 10.1016/j.jtho.2021.12.014_bib80
  article-title: Prognostic impact of PD-1 and PD-L1 expression in malignant pleural mesothelioma: an international multicenter study
  publication-title: Transl Lung Cancer Res
  doi: 10.21037/tlcr-20-1114
– volume: 33
  start-page: 255
  year: 2020
  ident: 10.1016/j.jtho.2021.12.014_bib36
  article-title: Interobserver variation in the assessment of the sarcomatoid and transitional components in biphasic mesotheliomas
  publication-title: Mod Pathol
  doi: 10.1038/s41379-019-0320-y
– volume: 127
  start-page: 325
  year: 2019
  ident: 10.1016/j.jtho.2021.12.014_bib55
  article-title: Immunocytochemistry for predictive biomarker testing in lung cancer cytology
  publication-title: Cancer Cytopathol
  doi: 10.1002/cncy.22137
– volume: 31
  start-page: 598
  year: 2018
  ident: 10.1016/j.jtho.2021.12.014_bib22
  article-title: Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: a multi-institutional study
  publication-title: Mod Pathol
  doi: 10.1038/modpathol.2017.170
– volume: 43
  start-page: 668
  year: 2011
  ident: 10.1016/j.jtho.2021.12.014_bib43
  article-title: The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma
  publication-title: Nat Genet
  doi: 10.1038/ng.855
– volume: 7
  start-page: 260
  year: 2019
  ident: 10.1016/j.jtho.2021.12.014_bib77
  article-title: Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial
  publication-title: Lancet Respir Med
  doi: 10.1016/S2213-2600(18)30420-X
– volume: 9
  start-page: 271
  year: 2014
  ident: 10.1016/j.jtho.2021.12.014_bib17
  article-title: The challenge of malignant pleural mesothelioma: new directions
  publication-title: J Thorac Oncol
  doi: 10.1097/JTO.0000000000000122
– volume: 13
  start-page: 2564
  year: 2021
  ident: 10.1016/j.jtho.2021.12.014_bib79
  article-title: Pathological characterization of Tumor Immune Microenvironment (TIME) in malignant pleural mesothelioma
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers13112564
– volume: 14
  start-page: 655
  year: 2001
  ident: 10.1016/j.jtho.2021.12.014_bib57
  article-title: Proximal-type epithelioid sarcoma: a clinicopathologic study of 20 cases
  publication-title: Mod Pathol
  doi: 10.1038/modpathol.3880368
– volume: 19
  start-page: 373
  year: 2006
  ident: 10.1016/j.jtho.2021.12.014_bib28
  article-title: Mesothelioma with rhabdoid features: an ultrastructural and immunohistochemical study of 10 cases
  publication-title: Mod Pathol
  doi: 10.1038/modpathol.3800543
– volume: 60
  start-page: 566
  year: 2010
  ident: 10.1016/j.jtho.2021.12.014_bib32
  article-title: Lymphohistiocytoid mesothelioma of the pleura
  publication-title: Pathol Int
  doi: 10.1111/j.1440-1827.2010.02560.x
– volume: 11
  start-page: 142
  year: 2016
  ident: 10.1016/j.jtho.2021.12.014_bib6
  article-title: The 2015 World Health Organization classification of tumors of the pleura: advances since the 2004 classification
  publication-title: J Thorac Oncol
  doi: 10.1016/j.jtho.2015.11.005
– volume: 25
  start-page: 1304
  year: 2001
  ident: 10.1016/j.jtho.2021.12.014_bib3
  article-title: Well-differentiated papillary mesothelioma
  publication-title: Am J Surg Pathol
  doi: 10.1097/00000478-200110000-00012
– volume: 20
  start-page: 1219
  year: 1996
  ident: 10.1016/j.jtho.2021.12.014_bib88
  article-title: Adenomatoid tumors of the pleura
  publication-title: Am J Surg Pathol
  doi: 10.1097/00000478-199610000-00007
SSID ssj0045048
Score 2.623199
SecondaryResourceType review_article
Snippet Substantial changes in the 2021 WHO Classification of Tumors of the Pleura and Pericardium since the 2015 WHO Classification include the following: (1) pleural...
SourceID proquest
pubmed
crossref
elsevier
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 608
SubjectTerms Biomarkers, Tumor - genetics
Histopathology
Homozygote
Humans
In Situ Hybridization, Fluorescence
Lung Neoplasms - pathology
Mesothelioma
Mesothelioma - pathology
Mesothelioma, Malignant
Pleura
Pleura - pathology
Pleural Neoplasms - pathology
Sequence Deletion
Tumor Suppressor Proteins - genetics
Ubiquitin Thiolesterase - genetics
World Health Organization
World Health Organization classification
Title The 2021 WHO Classification of Tumors of the Pleura: Advances Since the 2015 Classification
URI https://dx.doi.org/10.1016/j.jtho.2021.12.014
https://www.ncbi.nlm.nih.gov/pubmed/35026477
https://www.proquest.com/docview/2620077110
Volume 17
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELagKyEuiDflpSBxi4KS1E5SbhXsUrEvRFttJQ6W7STaViVBu8mFX8-MH-m2bFcLlyhyayfyfHa-Gc-DkPeqQEWCZUGichrQtBwEmYTljqmgklLkMs8wwPn4JBnP6Nc5m69tujq6pJEf1O9r40r-R6rQBnLFKNl_kGw3KDTAPcgXriBhuN5axjHMgn82PjXlLdHxpyOB0_YnltKxXgDfVkV7oSvxjMy5_6U_WeCybvQoEdsaYQdtbc4BNGqh_LpSGyb5iWhtkQ_nMeN3huXP2MMYoKtl9yH4IlbAdEUbTLCgi6PRql6sD4xGDZDX2rgC2hwAdlRrqQAlt_MLdJuryXlozmGKa9rcjpxeQR67sr0mOgfE39u-sUAsYVLOMaAzjrSJ10SnbubYPjnlB7OjIz7dn0_vkr0YlIu4R_ZGh9_PDt0XnLJQV13r3s0GWxm_wO1n7CI0uxQWTVymD8kDKzpvZODziNwpqsfk3rH1qXhCfgCKPHySByjyNjHg1aVnUIR3ABTPoOij5zDkaQzpnxBDW_2fktnB_vTTOLAlNwJFk6QJcprlKpOgBA9SGTMZ0kSwMlRZKIYqw1UN5CZNcxkpGlIB7H2YgsZflrEcikyGg2ekV9VV8YJ4mMxN6YyPGTCgohRMUMqGkRShiPOy7JPIzRtXNh89lkVZced4uOQ41xxngEcxh7nuE7_r88tkY7nx38yJg1s-aXgiB9zc2O-dkx2HzRZP0ERV1O0lx-oNYZoCZe6T50ao3XsMWBhjVPfLW_R-Re6vF8hr0msu2uINkNtGvrVY_AMckKBB
linkProvider Library Specific Holdings
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+2021+WHO+Classification+of+Tumors+of+the+Pleura%3A+Advances+Since+the+2015+Classification&rft.jtitle=Journal+of+thoracic+oncology&rft.au=Sauter%2C+Jennifer+L&rft.au=Dacic%2C+Sanja&rft.au=Galateau-Salle%2C+Francoise&rft.au=Attanoos%2C+Richard+L&rft.date=2022-05-01&rft.issn=1556-1380&rft.eissn=1556-1380&rft.volume=17&rft.issue=5&rft.spage=608&rft_id=info:doi/10.1016%2Fj.jtho.2021.12.014&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1556-0864&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1556-0864&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1556-0864&client=summon